array(40) {
  [0]=>
  string(4) "8902"
  ["article_id"]=>
  string(4) "8902"
  [1]=>
  string(95) "Beam Therapeutics licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline"
  ["article_title"]=>
  string(95) "Beam Therapeutics licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline"
  [2]=>
  string(150) "CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T pro"
  ["short_description"]=>
  string(150) "CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T pro"
  [3]=>
  string(655) "
CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing 
&#nl
The post Beam Therapeutics licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(655) "
CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing 
&#nl
The post Beam Therapeutics licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/beam-therapeutics-licenses-sirion-biotechs-lentiboost-technology-for-its-car-t-pipeline/"
  ["blog_url"]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/beam-therapeutics-licenses-sirion-biotechs-lentiboost-technology-for-its-car-t-pipeline/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8903"
  ["article_id"]=>
  string(4) "8903"
  [1]=>
  string(96) "Montreal Heart Institute, NYU Grossman School of Medicine collaborate on COVID-19 clinical trial"
  ["article_title"]=>
  string(96) "Montreal Heart Institute, NYU Grossman School of Medicine collaborate on COVID-19 clinical trial"
  [2]=>
  string(150) "The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammat"
  ["short_description"]=>
  string(150) "The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammat"
  [3]=>
  string(594) "
The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from 
&#nl
The post Montreal Heart Institute, NYU Grossman School of Medicine collaborate on COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(594) "
The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from 
&#nl
The post Montreal Heart Institute, NYU Grossman School of Medicine collaborate on COVID-19 clinical trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/montreal-heart-institute-covid-19/"
  ["blog_url"]=>
  string(86) "https://www.pharmaceutical-business-review.com/news/montreal-heart-institute-covid-19/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8904"
  ["article_id"]=>
  string(4) "8904"
  [1]=>
  string(50) "Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC"
  ["article_title"]=>
  string(50) "Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC"
  [2]=>
  string(150) "The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic ly"
  ["short_description"]=>
  string(150) "The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic ly"
  [3]=>
  string(546) "
The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small 
&#nl
The post Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(546) "
The latest approval from the European Commission (EC) authorises ALUNBRIG to be used as a monotherapy for the treatment of adults having anaplastic lymphoma kinase-positive (ALK+) advanced non-small 
&#nl
The post Takeda gets EU approval for ALUNBRIG in ALK+ NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/takeda-alunbrig-alk-nsclc/"
  ["blog_url"]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/takeda-alunbrig-alk-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8905"
  ["article_id"]=>
  string(4) "8905"
  [1]=>
  string(81) "Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease"
  ["article_title"]=>
  string(81) "Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease"
  [2]=>
  string(160) "In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosira"
  ["short_description"]=>
  string(160) "In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosira"
  [3]=>
  string(670) "
In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH). 
&#nl
The post Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(670) "
In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH). 
&#nl
The post Alnylam and Dicerna form RNAi Therapeutics collaboration on alpha-1 liver disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/alnylam-and-dicerna-form-rnai-therapeutics-collaboration-on-alpha-1-liver-disease/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/alnylam-and-dicerna-form-rnai-therapeutics-collaboration-on-alpha-1-liver-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8906"
  ["article_id"]=>
  string(4) "8906"
  [1]=>
  string(122) "Gilead Sciences, Second Genome announce strategic collaboration in biomarker and inflammatory bowel disease drug discovery"
  ["article_title"]=>
  string(122) "Gilead Sciences, Second Genome announce strategic collaboration in biomarker and inflammatory bowel disease drug discovery"
  [2]=>
  string(154) "Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platformâ„¢ to identify novel biomarkers associated "
  ["short_description"]=>
  string(154) "Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platformâ„¢ to identify novel biomarkers associated "
  [3]=>
  string(743) "
Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This 
&#nl
The post Gilead Sciences, Second Genome announce strategic collaboration in biomarker and inflammatory bowel disease drug discovery appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(743) "
Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This 
&#nl
The post Gilead Sciences, Second Genome announce strategic collaboration in biomarker and inflammatory bowel disease drug discovery appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(174) "https://www.pharmaceutical-business-review.com/news/gilead-sciences-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery/"
  ["blog_url"]=>
  string(174) "https://www.pharmaceutical-business-review.com/news/gilead-sciences-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:06"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9161"
  ["article_id"]=>
  string(4) "9161"
  [1]=>
  string(56) "ASTCT, ACCC and AACI launch initiative for CAR T therapy"
  ["article_title"]=>
  string(56) "ASTCT, ACCC and AACI launch initiative for CAR T therapy"
  [2]=>
  string(150) "This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely a"
  ["short_description"]=>
  string(150) "This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely a"
  [3]=>
  string(526) "
This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely and personalised care for 
&#nl
The post ASTCT, ACCC and AACI launch initiative for CAR T therapy appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(526) "
This collaboration aims to improve the evaluation process for CAR T therapy for cancer patients. It focuses on five crucial factors to ensure timely and personalised care for 
&#nl
The post ASTCT, ACCC and AACI launch initiative for CAR T therapy appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/astct-accc-aaci-therapy/"
  ["blog_url"]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/astct-accc-aaci-therapy/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9162"
  ["article_id"]=>
  string(4) "9162"
  [1]=>
  string(53) "Zokinvy gets Japanese approval for Progeria treatment"
  ["article_title"]=>
  string(53) "Zokinvy gets Japanese approval for Progeria treatment"
  [2]=>
  string(150) "The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric "
  ["short_description"]=>
  string(150) "The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric "
  [3]=>
  string(545) "
The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric disease characterised by accelerated aging. 
&#nl
The post Zokinvy gets Japanese approval for Progeria treatment appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(545) "
The approval from the Ministry of Health, Labor and Welfare (MHLW) marks a significant milestone in the treatment of the ultra-rare, fatal paediatric disease characterised by accelerated aging. 
&#nl
The post Zokinvy gets Japanese approval for Progeria treatment appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/zokinvy-progeria-treatment/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/zokinvy-progeria-treatment/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9163"
  ["article_id"]=>
  string(4) "9163"
  [1]=>
  string(49) "Kindeva Drug Delivery acquires Summit Biosciences"
  ["article_title"]=>
  string(49) "Kindeva Drug Delivery acquires Summit Biosciences"
  [2]=>
  string(150) "Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its po"
  ["short_description"]=>
  string(150) "Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its po"
  [3]=>
  string(524) "
Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer 
&#nl
The post Kindeva Drug Delivery acquires Summit Biosciences appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(524) "
Financial terms of the deal were undisclosed. The move is set to enhance Kindeva’s drug-delivery capabilities by adding a new platform to its portfolio. Kindeva CEO Milton Boyer 
&#nl
The post Kindeva Drug Delivery acquires Summit Biosciences appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/kindeva-drug-summit/"
  ["blog_url"]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/kindeva-drug-summit/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9164"
  ["article_id"]=>
  string(4) "9164"
  [1]=>
  string(66) "Eurofins Alphora completes Canadian biologics development facility"
  ["article_title"]=>
  string(66) "Eurofins Alphora completes Canadian biologics development facility"
  [2]=>
  string(150) "Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based t"
  ["short_description"]=>
  string(150) "Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based t"
  [3]=>
  string(578) "
Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins. The facility will provide a comprehensive 
&#nl
The post Eurofins Alphora completes Canadian biologics development facility appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(578) "
Located in Mississauga, Canada, the 3,300ft2 facility is designed for the development and scaling of monoclonal antibodies and other mammalian-based therapeutic proteins. The facility will provide a comprehensive 
&#nl
The post Eurofins Alphora completes Canadian biologics development facility appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/eurofins-biologics-facility/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/eurofins-biologics-facility/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9165"
  ["article_id"]=>
  string(4) "9165"
  [1]=>
  string(67) "US FDA updates Sanofi’s Dupixent label for atopic dermatitis"
  ["article_title"]=>
  string(67) "US FDA updates Sanofi’s Dupixent label for atopic dermatitis"
  [2]=>
  string(150) "This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a "
  ["short_description"]=>
  string(150) "This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a "
  [3]=>
  string(535) "
This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a fully human monoclonal 
&#nl
The post US FDA updates Sanofi’s Dupixent label for atopic dermatitis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(535) "
This label update is based on findings from the Phase III LIBERTY-AD-HAFT trial, the first to evaluate a biologic for this patient group. Dupixent, a fully human monoclonal 
&#nl
The post US FDA updates Sanofi’s Dupixent label for atopic dermatitis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/us-fda-updates-dupixent/"
  ["blog_url"]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/us-fda-updates-dupixent/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9166"
  ["article_id"]=>
  string(4) "9166"
  [1]=>
  string(70) "CARsgen’s CT011 receives IND clearance from China’s NMPA"
  ["article_title"]=>
  string(70) "CARsgen’s CT011 receives IND clearance from China’s NMPA"
  [2]=>
  string(150) "The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical rese"
  ["short_description"]=>
  string(150) "The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical rese"
  [3]=>
  string(556) "
The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection. CT011 is designed to target Glypican-3 
&#nl
The post CARsgen’s CT011 receives IND clearance from China’s NMPA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
The IND clearance has been received for patients with GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection. CT011 is designed to target Glypican-3 
&#nl
The post CARsgen’s CT011 receives IND clearance from China’s NMPA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/carsgens-ct011-nmpa/"
  ["blog_url"]=>
  string(72) "https://www.pharmaceutical-business-review.com/news/carsgens-ct011-nmpa/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9167"
  ["article_id"]=>
  string(4) "9167"
  [1]=>
  string(65) "GENESIS and Deciphera enter distribution agreement for Ripretinib"
  ["article_title"]=>
  string(65) "GENESIS and Deciphera enter distribution agreement for Ripretinib"
  [2]=>
  string(150) "This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal inclu"
  ["short_description"]=>
  string(150) "This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal inclu"
  [3]=>
  string(598) "
This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia, 
&#nl
The post GENESIS and Deciphera enter distribution agreement for Ripretinib appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(598) "
This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia, 
&#nl
The post GENESIS and Deciphera enter distribution agreement for Ripretinib appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(93) "https://www.pharmaceutical-business-review.com/news/genesis-deciphera-distribution-agreement/"
  ["blog_url"]=>
  string(93) "https://www.pharmaceutical-business-review.com/news/genesis-deciphera-distribution-agreement/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:32"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}